Retrospective Review Of Uveal Melanoma Patients Treated With Fractionated Stereotactic Radiotherapy

Objectives: Last decades, radiotherapy displaced surgery as an effective organ preserving option for uveal melanoma treatment if tumor diameter and localisation permits. We aimed to report our experience about the management of uveal melanoma treated with CyberKnife fractionated stereotactic radiotherapy. Materials and Methods: We retrospectively evaluated 31 uveal melanoma patients treated with CyberKnife fractionated stereotactic radiotherapy. 29 was medium and 2 was large sized tumor. Results: The median follow-up was 26 months. Overall survival, metastasis free survival, local control and eye retention rates for 2- and 4-year were 94.7%, 94.7%; 89.1%, 81%; 92.9%, 81.3% and 82.1%, 61.9%, respectively. Conclusion: In view of our experience, it may be preferable to use CyberKnife fractionated stereotactic radiotherapy for patients with uveal melanoma as a noninvasive, precise radiotherapy technique.